Management of the clotting system: a European perspective

Brigitte E Ickx1, David Faraoni

  • 1Department of Anesthesiology, Hôpital Universitaire Erasme, Brussels, Belgium. brigitte.ickx@erasme.ulb.ac.be

Insights

Managing coagulation in cardiac surgery patients is complex due to aging populations and new antithrombotic drugs. This review covers perioperative treatments and monitoring for bleeding and coagulopathy.

Area of Science:

  • Anesthesiology
  • Cardiovascular Surgery
  • Hematology

Background:

  • Cardiovascular surgery patients are aging and have comorbidities, complicating coagulation management.
  • Pre-existing treatments with anticoagulants and antiplatelet agents are common.
  • Perioperative bleeding and coagulopathy pose significant risks.

Purpose of the Study:

  • To review current knowledge and available treatments for coagulation management in cardiac surgery.
  • To discuss new antithrombotic agents and their preoperative implications.
  • To highlight advancements in bleeding and coagulopathy treatment and monitoring.

Main Methods:

  • Literature review of perioperative coagulation management in cardiovascular surgery.
  • Discussion of new antithrombotic drugs and their clinical use.
  • Overview of hemostatic agents and monitoring devices available in Europe.

Main Results:

  • New antithrombotic drugs increase the complexity of perioperative coagulation management.
  • Various products for treating bleeding and coagulopathy are available in Europe.
  • Novel monitoring devices, particularly for platelet function, are emerging.

Conclusions:

  • Coagulation management in cardiac surgery is increasingly complex due to new pharmacotherapies.
  • Improved and developed monitoring strategies are essential, especially for platelet function assessment.
  • Effective perioperative management requires a comprehensive understanding of new agents and monitoring tools.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...